CTOs on the Move

Blaze Bioscience

www.blazebioscience.com

 
Blaze Bioscience, Inc. is a privately held biotechnology company focused on guided therapies. Blaze was founded in 2010 by Dr. Jim Olson, a pediatric neuro-oncologist at the Fred Hutchinson Cancer Research Center and Seattle Children`s Hospital, and Heather Franklin, a former senior business executive from ZymoGenetics. Blaze is working to develop Tumor Paint products and Optide*-based guided therapeutics.
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million

Executives

Name Title Contact Details

Funding

Blaze Bioscience raised $16.15M on 10/12/2017

Similar Companies

Akriveia Therapeutics

`Akrevia` is derived from the Greek word for `precision`, which reflects our mission to precisely deliver the activity of potent, tailored immunotherapies exactly where it’s needed.

BMG Labtech

BMG Labtech is a Cary, NC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Plexxikon

Plexxikon is a Berkeley, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Conversant Biologics

Conversant Biologics is a Huntsville, AL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

InnovaPrep

InnovaPrep is engaged in product development, manufacturing, sales, service, and related out-licensing of a collection of novel technologies enabling rapid detection of biological particles and pathogens. Our core business is biological sample collection, concentration and preparation. The company has commercialized a collection of market-disruptive platform technologies for rapid, automated concentration of biological particles. InnovaPrep`s 35 pending and awarded patents apply to highly efficient collection, recovery, and concentration of biological particles from air, surfaces, and liquids. Our elution process underlies many of these patents and enables recovery of particles from filters, membranes, surfaces, and objects. The primary utility for these technologies is to greatly improve the way biological samples, especially those containing pathogenic organisms, are collected and prepared for analysis beyond the state-of-the-art. These technologies fill a critical void that currently severely limits application of the most advanced biological detection systems to the billions of microbiological tests performed annually. Markets served: Biodefense, food safety, water safety, biopharma, clinical research, animal health, environmental monitoring and others.